In a phase 3 trial, the anti-38 monoclonal antibody daratumumab (Darzalex, Johnson & Johnson) substantially delayed or prevented transformation of smoldering to active multiple myeloma (MM).
Compared with active monitoring, daratumumab not only delayed the initiation of first-line MM therapy, but it showed favorable rates of progression-free survival (PFS) and a trend for an overall survival advantage, reported Meletios-Athanasios Dimopoulos, MD, PhD, the chairman of the Department of